These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 18784279)

  • 1. Experience with irinotecan for the treatment of malignant glioma.
    Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS
    Neuro Oncol; 2009 Feb; 11(1):80-91. PubMed ID: 18784279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
    Friedman HS; Keir ST; Houghton PJ
    Cancer; 2003 May; 97(9 Suppl):2359-62. PubMed ID: 12712457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
    Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
    Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.
    Buckner JC; Reid JM; Wright K; Kaufmann SH; Erlichman C; Ames M; Cha S; O'Fallon JR; Schaaf LJ; Miller LL
    Cancer; 2003 May; 97(9 Suppl):2352-8. PubMed ID: 12712456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan: promising activity in the treatment of malignant glioma.
    Reardon DA; Friedman HS; Powell JB; Gilbert M; Yung WK
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):9-14. PubMed ID: 12800600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
    Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
    Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends.
    Sasine JP; Savaraj N; Feun LG
    Anticancer Agents Med Chem; 2010 Nov; 10(9):683-96. PubMed ID: 21235438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide in combination with other cytotoxic agents.
    Prados M
    Semin Oncol; 2001 Aug; 28(4 Suppl 13):24-33. PubMed ID: 11550136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
    Loghin ME; Prados MD; Wen P; Junck L; Lieberman F; Fine H; Fink KL; Metha M; Kuhn J; Lamborn K; Chang SM; Cloughesy T; DeAngelis LM; Robins IH; Aldape KD; Yung WK
    Clin Cancer Res; 2007 Dec; 13(23):7133-8. PubMed ID: 18056194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered irinotecan metabolism in a patient receiving phenytoin.
    Mathijssen RH; Sparreboom A; Dumez H; van Oosterom AT; de Bruijn EA
    Anticancer Drugs; 2002 Feb; 13(2):139-40. PubMed ID: 11901305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
    Seystahl K; Wiestler B; Hundsberger T; Happold C; Wick W; Weller M; Wick A
    Eur Neurol; 2013; 69(2):95-101. PubMed ID: 23182901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
    Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
    Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
    Hare CB; Elion GB; Houghton PJ; Houghton JA; Keir S; Marcelli SL; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 1997; 39(3):187-91. PubMed ID: 8996518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.
    Clarke JL; Molinaro AM; Cabrera JR; DeSilva AA; Rabbitt JE; Prey J; Drummond DC; Kim J; Noble C; Fitzgerald JB; Chang SM; Butowski NA; Taylor JW; Park JW; Prados MD
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):603-610. PubMed ID: 28233053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
    Cloughesy TF; Filka E; Kuhn J; Nelson G; Kabbinavar F; Friedman H; Miller LL; Elfring GL
    Cancer; 2003 May; 97(9 Suppl):2381-6. PubMed ID: 12712460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
    Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
    Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
    Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
    Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan in epithelial ovarian cancer.
    Gershenson DM
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):29-31. PubMed ID: 12109803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
    Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
    Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
    J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.